Literature DB >> 10882055

Potent adjuvant effect by anti-CD40 in collagen-induced arthritis. Enhanced disease is accompanied by increased production of collagen type-II reactive IgG2a and IFN-gamma.

A C Tellander1, E Michaëlsson, C Brunmark, M Andersson.   

Abstract

Collagen type II-induced arthritis (CIA) is an experimental model of rheumatoid arthritis, an autoimmune inflammatory disease of the peripheral joints in humans. CD40 interaction with its ligand CD154 (CD40L) has been shown to be an obligatory step in the initiation of autoimmune disease in several animal models. In this study we report on the effect of CD40 stimulation in CIA induced by immunization with type II collagen (CII) in CFA or IFA. We found that the administration of stimulatory anti-CD40 mAb resulted in earlier onset and more severe disease in IFA-CII-immunized mice. The mAb treatment resulted in markedly elevated titers of CII-specific IgG2a antibodies whereas CII-specific IgG1 titers were unaffected. Draining lymph node cell cultures from mice treated with anti-CD40 exhibited significantly increased IFN-gamma production compared to cultures from control antibody-treated mice. In conclusion, our results indicate that the level of CD40 activation during the induction of an autoimmune response may determine the severity of the resulting disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882055     DOI: 10.1006/jaut.2000.0374

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  14 in total

Review 1.  CD40 and autoimmunity: the dark side of a great activator.

Authors:  Anna L Peters; Laura L Stunz; Gail A Bishop
Journal:  Semin Immunol       Date:  2009-10       Impact factor: 11.130

Review 2.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

3.  Resistance to development of collagen-induced arthritis in C57BL/6 mice is due to a defect in secondary, but not in primary, immune response.

Authors:  Meng Pan; Insoo Kang; Joe Craft; Zhinan Yin
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

Review 4.  CD154: the atherosclerotic risk factor in rheumatoid arthritis?

Authors:  Ghada S Hassan; Daniel Yacoub; Nada Alaaeddine; Amal Nadiri; Yahye Merhi; Walid Mourad
Journal:  Arthritis Res Ther       Date:  2013-02-22       Impact factor: 5.156

Review 5.  The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy.

Authors:  Boel De Paepe; Kim K Creus; Jan L De Bleecker
Journal:  Clin Dev Immunol       Date:  2011-10-23

Review 6.  CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Nada Alaaeddine; Ghada S Hassan; Daniel Yacoub; Walid Mourad
Journal:  Clin Dev Immunol       Date:  2011-10-24

Review 7.  Immune checkpoint receptors in regulating immune reactivity in rheumatic disease.

Authors:  Sabrina Ceeraz; Elizabeth C Nowak; Christopher M Burns; Randolph J Noelle
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

8.  RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis.

Authors:  Xiufen Zheng; Motohiko Suzuki; Xusheng Zhang; Thomas E Ichim; Fei Zhu; Hong Ling; Aminah Shunnar; Michael H Wang; Bertha Garcia; Robert D Inman; Wei-Ping Min
Journal:  Arthritis Res Ther       Date:  2010-01-26       Impact factor: 5.156

9.  OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis.

Authors:  Emily Gwyer Findlay; Lynett Danks; Jodie Madden; Mary M Cavanagh; Kay McNamee; Fiona McCann; Robert J Snelgrove; Stevan Shaw; Marc Feldmann; Peter Charles Taylor; Nicole J Horwood; Tracy Hussell
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

10.  Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway.

Authors:  Gang Li; Dorothée Diogo; Di Wu; Jim Spoonamore; Vlado Dancik; Lude Franke; Fina Kurreeman; Elizabeth J Rossin; Grant Duclos; Cathy Hartland; Xuezhong Zhou; Kejie Li; Jun Liu; Philip L De Jager; Katherine A Siminovitch; Alexandra Zhernakova; Soumya Raychaudhuri; John Bowes; Steve Eyre; Leonid Padyukov; Peter K Gregersen; Jane Worthington; Namrata Gupta; Paul A Clemons; Eli Stahl; Nicola Tolliday; Robert M Plenge
Journal:  PLoS Genet       Date:  2013-05-16       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.